Canada markets open in 4 hours 6 minutes

Cybin Inc. (CYBN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.3499-0.0062 (-1.74%)
At close: 04:00PM EDT
0.3410 -0.01 (-2.54%)
Pre-Market: 04:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3561
Open0.3567
Bid0.0000 x 800
Ask0.3550 x 900
Day's Range0.3415 - 0.3599
52 Week Range0.2100 - 0.7380
Volume2,641,890
Avg. Volume5,217,660
Market Cap265.816M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Business Wire

    Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

    TORONTO, May 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024.

  • Business Wire

    Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

    TORONTO, May 06, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.

  • Business Wire

    Cybin to Participate at the 27th Annual Milken Institute Global Conference

    TORONTO, April 25, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled "Collaborating for Improved Mental Health." The Conference will